Temat: "GEMCITABINE" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells.
Autorzy:: Larson AC; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Knoche SM; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Brumfield GL; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Doty KR; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Gephart BD; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Moore-Saufley PR; Departments of Psychology and Biology, University of Nebraska Omaha, Omaha, NE 68192, USA.
Solheim JC; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 11; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:: Journal Article
MeSH Terms:: Gemcitabine*
Pancreatic Neoplasms*/metabolism
Humans ; Deoxycytidine/therapeutic use ; Antigen Presentation ; Histocompatibility Antigens Class I/genetics ; Peptides ; Antigens, Neoplasm/therapeutic use ; Pancreatic Hormones ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: [Gemcitabine long-term maintenance chemotherapy benefits patients with survival: a multicenter, real-world study of advanced breast cancer treatment in China].
Autorzy:: Yue J; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Song GH; Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Li HP; Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Sun T; Department of Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Song LH; Department of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Tong ZS; Department of Breast Oncology, Tianjin Medical University Cancer Hospital, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Zhang LL; Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.
Song ZC; Breast Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Ouyang QC; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha 410006, China.
Yang J; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China.
Pan YY; Department of Medical Oncology, Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, China.
Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.; Pokaż więcej
Źródło:: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Mar 23; Vol. 46 (3), pp. 249-255.
Typ publikacji:: Multicenter Study; English Abstract; Journal Article
MeSH Terms:: Breast Neoplasms*/pathology
Gemcitabine*
Female ; Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/therapeutic use ; Maintenance Chemotherapy ; Treatment Outcome ; Adult ; Aged

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Gemcitabine Inhibits the Progression of Pancreatic Cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner.
Autorzy:: Cao P; Department of General Surgery,The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhang W; Department of General Surgery,The First Affiliated Hospital of Soochow University, Suzhou, China.
Qiu J; Department of General Surgery,The First Affiliated Hospital of Soochow University, Suzhou, China.
Tang Z; Department of General Surgery,The First Affiliated Hospital of Soochow University, Suzhou, China.
Xue X; Department of General Surgery,The First Affiliated Hospital of Soochow University, Suzhou, China.
Feng T; Department of Infectious Disease,The First Affiliated Hospital of Soochow University, Suzhou, China.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 259-271. Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:: Journal Article
MeSH Terms:: Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Humans ; Adenine ; Adenosine/pharmacology ; RNA Splicing Factors ; Cell Cycle Proteins

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Ionophore-Based Polymeric Sensors for Potentiometric Assay of the Anticancer Drug Gemcitabine in Pharmaceutical Formulation: A Comparative Study.
Autorzy:: Mostafa GAE; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
El-Tohamy MF; Department of Chemistry, College of Science, King Saud University, Riyadh 11495, Saudi Arabia.
Ali EA; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Al-Salahi R; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Attwa MW; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
AlRabiah H; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2023 Nov 12; Vol. 28 (22). Date of Electronic Publication: 2023 Nov 12.
Typ publikacji:: Journal Article
MeSH Terms:: Gemcitabine*
Antineoplastic Agents*
Drug Compounding ; Ionophores ; Polymers ; Potentiometry/methods ; Polyvinyl Chloride

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer.
Autorzy:: Zhou L; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. .; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. .; Unit of Day Surgery Center, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. .
Du K; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Unit of Day Surgery Center, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dai Y; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Unit of Day Surgery Center, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zeng Y; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Unit of Day Surgery Center, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Luo Y; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ren M; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Pan W; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Liu Y; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang L; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhu R; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Feng D; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Tian F; Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. .
Gu C; Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. .; Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. .; Unit of Day Surgery Center, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2024 Jan 13; Vol. 22 (1), pp. 55. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:: Journal Article
MeSH Terms:: Gemcitabine*
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Humans ; Metabolic Reprogramming ; Base Sequence ; Sequence Analysis, RNA ; Tumor Microenvironment ; Fatty Acid Synthase, Type I/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma.
Autorzy:: Zhu Z; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.; 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Tang H; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Ying J; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Cheng Y; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Wang X; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Wang Y; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Bai C; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.; Pokaż więcej
Źródło:: Cancer biology & medicine [Cancer Biol Med] 2023 Aug 29; Vol. 20 (10).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gemcitabine*
Adenocarcinoma*
Humans ; Deoxycytidine/adverse effects ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Paclitaxel ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway.
Autorzy:: Lin K; Department of Gastrointestinal Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhou E; Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shi T; Department of Hepatobiliary Surgery, The Afliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.
Zhang S; Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhang J; Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zheng Z; Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pan Y; Medical Faculty of Ludwig Maximilians, University of Munich-Munich, Bayern, Germany.
Gao W; Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. .
Yu Y; Department of Hepatobiliary Surgery, The Afliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Aug 22; Vol. 42 (1), pp. 217. Date of Electronic Publication: 2023 Aug 22.
Typ publikacji:: Journal Article
MeSH Terms:: Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Humans ; Phosphatidylinositol 3-Kinases ; Proto-Oncogene Proteins c-akt ; Ubiquitin-Specific Peptidase 7 ; RNA Stability ; PTEN Phosphohydrolase/genetics ; Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
Autorzy:: Ramjeesingh R; Division of Medical Oncology, Department of Medicine, Nova Scotia Health, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
Chaudhury P; Department of Surgery and Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC H4A 3J1, Canada.
Tam VC; Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, AB T2N 4N2, Canada.
Roberge D; Department of Radiology, Radiation Oncology and Nuclear Medicine, University of Montreal, Montreal, QC H3T 1A4, Canada.
Lim HJ; Division of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
Knox JJ; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Asselah J; Department of Medicine, Division of Medical Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Doucette S; IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.
Chhiber N; IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.
Goodwin R; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Jul 25; Vol. 30 (8), pp. 7132-7150. Date of Electronic Publication: 2023 Jul 25.
Typ publikacji:: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
MeSH Terms:: Biliary Tract Neoplasms*/drug therapy
Cisplatin*/therapeutic use
Gemcitabine*/therapeutic use
Humans ; Canada ; Capecitabine/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Autorzy:: Rasmussen LS; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Winther SB; Department of Oncology, Odense University Hospital, Odense, Denmark.
Chen IM; Department of Oncology, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
Weber B; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Ventzel L; Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark.
Liposits G; Department of Oncology, Gødstrup Hospital, Herning, Denmark.
Johansen JS; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Detlefsen S; Department of Pathology, Odense University Hospital, and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Egendal I; Center for Clinical Data Science (CLINDA), and Clinical Cancer Research Center, Aalborg University and, Aalborg University Hospital, Aalborg, Denmark.
Shim S; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Christensen S; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Pfeiffer P; Department of Oncology, Odense University Hospital, and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Ladekarl M; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2023 Jun 16; Vol. 23 (1), pp. 552. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:: Multicenter Study; Clinical Trial, Phase II; Journal Article
MeSH Terms:: Gemcitabine*
Pancreatic Neoplasms*/pathology
Humans ; Deoxycytidine ; Quality of Life ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Paclitaxel ; Albumins ; Randomized Controlled Trials as Topic ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Autorzy:: Koh EK; Department of Research Center, Dongnam Institute of Radiological and Medical Sciences, Busan, 46033, South Korea.; Department of Biochemistry, Pusan National University School of Medicine, Yangsan, 50612, South Korea.
Lee HR; Department of Research Center, Dongnam Institute of Radiological and Medical Sciences, Busan, 46033, South Korea.
Son WC; Department of Research Center, Dongnam Institute of Radiological and Medical Sciences, Busan, 46033, South Korea.
Park GY; Department of Research Center, Dongnam Institute of Radiological and Medical Sciences, Busan, 46033, South Korea.
Kim J; Department of Research Center, Dongnam Institute of Radiological and Medical Sciences, Busan, 46033, South Korea.
Bae JH; Department of Biochemistry, Pusan National University School of Medicine, Yangsan, 50612, South Korea. .
Park YS; Department of Research Center, Dongnam Institute of Radiological and Medical Sciences, Busan, 46033, South Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 May 11; Vol. 13 (1), pp. 7656. Date of Electronic Publication: 2023 May 11.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gemcitabine*
Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/metabolism
Humans ; Animals ; Mice ; Leukocytes, Mononuclear ; Neoplasm Recurrence, Local/metabolism ; Killer Cells, Natural ; Immunotherapy/methods ; Cell Line, Tumor ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
Autorzy:: Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Ping L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Tang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zheng W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Ying Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Wu M; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Feng F; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Lin N; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Tu M; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China. .; Pokaż więcej
Źródło:: BMC medicine [BMC Med] 2024 Mar 07; Vol. 22 (1), pp. 107. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:: Clinical Trial, Phase II; Journal Article
MeSH Terms:: Hodgkin Disease*/drug therapy
Hodgkin Disease*/etiology
Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*
Antibodies, Monoclonal, Humanized*
Humans ; Gemcitabine ; Oxaliplatin/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
Autorzy:: Yang Z; Department of Gastroenterology, Guangxi Medical University Cancer Hospital, No 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Chen F; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Wei D; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Chen F; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Jiang H; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China. .
Qin S; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 268. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/pathology
Animals ; Humans ; Gemcitabine ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Apoptosis ; Early Growth Response Protein 1/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
Autorzy:: Gueiderikh A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Tarabay A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Abdelouahab M; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Smolenschi C; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Tanguy ML; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Valery M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Malka D; Département d'oncologie médicale, Institut Mutualiste Montsouris, 75014, Paris, France.
Pudlarz T; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Fuerea A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Boige V; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Hollebecque A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Ducreux M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Boilève A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France. .; Université Paris Saclay, 91471, Orsay, France. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 272. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/pathology
Adenocarcinoma*/pathology
Humans ; Gemcitabine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Retrospective Studies ; Erlotinib Hydrochloride/therapeutic use ; Deoxycytidine ; Fluorouracil ; Leucovorin/therapeutic use ; Paclitaxel ; Albumins

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
Autorzy:: Zhang J; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yang M; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhang D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chen Z; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Zhu H; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 13; Vol. 24 (1), pp. 202. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/surgery
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Antibodies, Monoclonal, Humanized*
Humans ; Cisplatin/therapeutic use ; Gemcitabine ; Retrospective Studies ; Deoxycytidine/adverse effects ; Muscles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model.
Autorzy:: Zhang K; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Wuri Q; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Cai Z; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Qu X; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Zhang S; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Wu H; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Wu J; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Wang C; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.
Yu X; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.; Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.
Kong W; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.; Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.
Zhang H; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 04; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Neoplasms*/therapy
Vaccines, DNA*/immunology
Vaccines, DNA*/therapeutic use
Cancer Vaccines*/immunology
Cancer Vaccines*/therapeutic use
Animals ; Female ; Mice ; CD8-Positive T-Lymphocytes ; Dendritic Cells ; Gemcitabine ; Mice, Inbred C57BL

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Design of the New Closo -Dodecarborate-Containing Gemcitabine Analogue for the Albumin-Based Theranostics Composition.
Autorzy:: Raskolupova VI; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Wang M; Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.
Dymova MA; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Petrov GO; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Shchudlo IM; Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia.
Taskaev SY; Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.; Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia.
Abramova TV; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Godovikova TS; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.; Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.
Silnikov VN; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.
Popova TV; Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia.; Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2023 Mar 15; Vol. 28 (6). Date of Electronic Publication: 2023 Mar 15.
Typ publikacji:: Journal Article
MeSH Terms:: Gemcitabine*
Precision Medicine*
Humans ; Boron Compounds ; Albumins

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study.
Autorzy:: Watson S; Department of Medical Oncology, Curie Institute, Paris, France.
Verret B; Division of Cancer Medicine, Gustave Roussy, Villejuif, France.
Ropert S; Department of Medical Oncology, Antony Private Hospital, Antony, France.
Adam J; Division of Biology and Pathology, Gustave Roussy, Villejuif, France.
Bahleda R; Division of Drug Development (DITEP), Gustave Roussy, Villejuif, France.
Briand S; Department of Orthopedic Surgery, Kremlin-Bicêtre Teaching Hospital, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Cavalcanti A; Division of Surgery, Gustave Roussy, Villejuif, France.
Chamseddine AN; Division of International Patients Care, Gustave Roussy, Villejuif, France.
Court C; Department of Orthopedic Surgery, Kremlin-Bicêtre Teaching Hospital, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Fadel E; Department of Thoracic Surgery, Marie Lannelongue Teaching Hospital, Université Paris-Saclay, Le Plessis-Robinson, France.
Faron M; Division of Surgery, Gustave Roussy, Villejuif, France.
Haddag-Miliani L; Department of Medical Imaging, Gustave Roussy, Villejuif, France.
Henon C; Division of Cancer Medicine, Gustave Roussy, Villejuif, France.
Pechoux CL; Division of Radiation Oncology, Gustave Roussy, Villejuif, France.
Levy A; Division of Radiation Oncology, Gustave Roussy, Villejuif, France.
Mercier O; Department of Thoracic Surgery, Marie Lannelongue Teaching Hospital, Université Paris-Saclay, Le Plessis-Robinson, France.
Ngo C; Division of Biology and Pathology, Gustave Roussy, Villejuif, France.
Honoré C; Division of Surgery, Gustave Roussy, Villejuif, France.
Cesne AL; Division of International Patients Care, Gustave Roussy, Villejuif, France.
Mir O; Division of Cancer Medicine, Gustave Roussy, Villejuif, France.; Department of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (3), pp. 3160-3166. Date of Electronic Publication: 2022 Aug 15.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Gemcitabine*
Hemangiosarcoma*/etiology
Adult ; Humans ; Retrospective Studies ; Deoxycytidine/therapeutic use ; Taxoids/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Autorzy:: Cheng K; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Zhou Z; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Chen Q; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Chen Z; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Cai Y; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Cai H; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Wu S; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Gao P; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Cai Y; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Zhou J; Division of Liver Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Wang X; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Wu Z; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China. .
Peng B; Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Apr 10; Vol. 14 (1), pp. 8389. Date of Electronic Publication: 2024 Apr 10.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Humans ; Gemcitabine ; Cell Proliferation ; Cell Line, Tumor ; Cell Cycle ; Mitogen-Activated Protein Kinase Kinases ; Cyclin-Dependent Kinase 4

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
Autorzy:: Hawkins HJ; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Yacob BW; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Brown ME; Section of Developmental Biology, Dept. of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Goldstein BR; Section of Developmental Biology, Dept. of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Arcaroli JJ; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Bagby SM; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Hartman SJ; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Macbeth M; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Goodspeed A; University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.; Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Danhorn T; University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.; Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Lentz RW; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Lieu CH; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Leal AD; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Messersmith WA; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Dempsey PJ; Section of Developmental Biology, Dept. of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Pitts TM; University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Apr 10; Vol. 19 (4), pp. e0298808. Date of Electronic Publication: 2024 Apr 10 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Animals ; Mice ; Humans ; Gemcitabine ; Wnt Signaling Pathway ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Mice, Nude ; Cell Proliferation ; Cell Line, Tumor ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Organoids/metabolism ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
Autorzy:: Moussa M; Department of Urology, Lebanese University, Beirut. .
Abou Chakra M; Department of Urology, Lebanese University, Beirut . .
Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC. .
Papatsoris A; Department of Urology, Lebanese University, Beirut. .
Farahat Y; Urology Department, Sheikh Khalifa General Hospital, Umm Al Quwain. .
O'Donnell MA; Department of Urology, University of Iowa, Iowa City, IA. .; Pokaż więcej
Źródło:: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica [Arch Ital Urol Androl] 2024 Mar 19; Vol. 96 (1), pp. 12244. Date of Electronic Publication: 2024 Mar 19.
Typ publikacji:: Journal Article
MeSH Terms:: Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/pathology
Humans ; Mitomycin/therapeutic use ; Gemcitabine ; BCG Vaccine/therapeutic use ; Urologists ; Docetaxel/therapeutic use ; Arabs ; Neoplasm Invasiveness ; Adjuvants, Immunologic/therapeutic use ; Neoplasm Recurrence, Local

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""GEMCITABINE"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji